mitoxantrone has been researched along with Disease Models, Animal in 31 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Mitoxantrone (MX) has been approved by the Food and Drug Administration for the treatment of rapidly progressive multiple sclerosis (MS)." | 8.82 | Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. ( Dubois, B; Gonsette, RE, 2004) |
| "The side effects of cancer chemotherapeutic agents such as mitoxantrone (MIT) in multiple sclerosis (MS) patients justify the search for less toxic drugs." | 7.74 | Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. ( Bai, XF; Campagnolo, DI; Dorr, RT; Huang, J; Piao, WH; Shi, FD; Vollmer, TL; Wong, R, 2007) |
| "When rats with developing or established adjuvant arthritis are treated with mitoxantrone, the hind paw inflammation associated with the disease is inhibited." | 7.67 | Studies of the effect of mitoxantrone on adjuvant induced arthritis in rats. ( Kerwar, SS; Oronsky, AL; Sloboda, AE, 1986) |
| "Mitoxantrone (MX) has been approved by the Food and Drug Administration for the treatment of rapidly progressive multiple sclerosis (MS)." | 4.82 | Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity. ( Dubois, B; Gonsette, RE, 2004) |
| "CT26 murine colorectal cancer cells were treated with physiologic levels of the potent inducer of immunogenic cell death mitoxantrone (MTX)." | 3.91 | Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases. ( Kunda, NM; Maker, AV; Prabhakar, BS; Qiao, G; Qin, J; Tulla, K, 2019) |
| "Mitoxantrone (MXT) is an androstenedione that is used to treat cancers and progressive forms of multiple sclerosis; however, its use is limited by its cardiotoxicity." | 3.85 | Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. ( Bradley, J; Burn, B; Chuang, G; Coy, DH; Maderdrut, JL; Subramaniam, V; Varner, KJ; Xia, H, 2017) |
| " We treated the Buff/Mna rats with mitoxantrone and measured the depletion of B/T cells in parallel with proteinuria." | 3.80 | Is there B cell involvement in a rat model of spontaneous idiopathic nephrotic syndrome treated with LF15-0195? ( Dantal, J; Le Berre, L; Tilly, G, 2014) |
| "Mitoxantrone is one of the few FDA-approved drugs available to treat rapidly progressing forms of multiple sclerosis; however, its utilization is compromised by a cardiotoxic potential and the risk of mitoxantrone-induced leukemia." | 3.77 | A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity. ( Gunning, W; Hacker, M; Kiraly, A; Koffman, B; Quinn, A; Rasche, S, 2011) |
| "The side effects of cancer chemotherapeutic agents such as mitoxantrone (MIT) in multiple sclerosis (MS) patients justify the search for less toxic drugs." | 3.74 | Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis. ( Bai, XF; Campagnolo, DI; Dorr, RT; Huang, J; Piao, WH; Shi, FD; Vollmer, TL; Wong, R, 2007) |
| " The purpose of this study was to evaluate the efficacy of combined therapy using the cyclooxygenase inhibitor, piroxicam, and mitoxantrone against a relevant canine model of human invasive bladder cancer." | 3.72 | Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma. ( Bravo, L; Chun, R; Dernell, WS; Henry, CJ; Higginbotham, ML; Jorgensen, L; Madewell, BR; McCaw, DL; Scott, MA; Sheafor, S; Straw, RC; Turnquist, SE; Tyler, JW, 2003) |
| "The present study was designed to test the efficacy of intratumoral biopolymer-mediated mitoxantrone chemotherapy in the rat brain 9L glioma model." | 3.72 | Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors. ( Bellinzona, M; Hussein, S; Roser, F; Saini, M; Samii, M, 2004) |
| "Since the efficacy of current immunomodulatory and immunosuppressive therapies (beta-interferons, glatiramer acetate, mitoxantrone) is limited, it is necessary to develop new strategies for the treatment of multiple sclerosis." | 3.71 | [New approaches in research of therapy of multiple sclerosis]. ( Cepok, S; Hemmer, B; Nessler, S; Sommer, N, 2001) |
| "When rats with developing or established adjuvant arthritis are treated with mitoxantrone, the hind paw inflammation associated with the disease is inhibited." | 3.67 | Studies of the effect of mitoxantrone on adjuvant induced arthritis in rats. ( Kerwar, SS; Oronsky, AL; Sloboda, AE, 1986) |
| "Dexrazoxane is an established treatment option in extravasation of the classic anthracyclines such as doxorubicin, epirubicin, and daunorubicin." | 1.38 | Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane. ( Jensen, PB; Langer, SW; Sehested, M; Thougaard, AV, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (9.68) | 18.7374 |
| 1990's | 1 (3.23) | 18.2507 |
| 2000's | 13 (41.94) | 29.6817 |
| 2010's | 13 (41.94) | 24.3611 |
| 2020's | 1 (3.23) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 2 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Subramaniam, V | 1 |
| Chuang, G | 1 |
| Xia, H | 1 |
| Burn, B | 1 |
| Bradley, J | 1 |
| Maderdrut, JL | 1 |
| Coy, DH | 1 |
| Varner, KJ | 1 |
| Qin, J | 1 |
| Kunda, NM | 1 |
| Qiao, G | 1 |
| Tulla, K | 1 |
| Prabhakar, BS | 1 |
| Maker, AV | 1 |
| Lang, Y | 1 |
| Li, Y | 2 |
| Jasperson, D | 1 |
| Henningson, J | 1 |
| Lee, J | 1 |
| Ma, J | 1 |
| Duff, M | 1 |
| Liu, H | 1 |
| Bai, D | 1 |
| McVey, S | 1 |
| Richt, JA | 1 |
| Ikegami, T | 1 |
| Wilson, WC | 1 |
| Ma, W | 1 |
| Ma, MT | 1 |
| He, M | 1 |
| Wang, Y | 1 |
| Jiao, XY | 1 |
| Zhao, L | 1 |
| Bai, XF | 2 |
| Yu, ZJ | 1 |
| Wu, HZ | 1 |
| Sun, ML | 1 |
| Song, ZG | 1 |
| Wei, MJ | 1 |
| Le Berre, L | 1 |
| Tilly, G | 1 |
| Dantal, J | 1 |
| Eleuteri, S | 1 |
| Di Giovanni, S | 1 |
| Rockenstein, E | 1 |
| Mante, M | 1 |
| Adame, A | 1 |
| Trejo, M | 1 |
| Wrasidlo, W | 1 |
| Wu, F | 1 |
| Fraering, PC | 1 |
| Masliah, E | 1 |
| Lashuel, HA | 1 |
| Griesi-Oliveira, K | 1 |
| Acab, A | 1 |
| Gupta, AR | 1 |
| Sunaga, DY | 1 |
| Chailangkarn, T | 1 |
| Nicol, X | 1 |
| Nunez, Y | 1 |
| Walker, MF | 1 |
| Murdoch, JD | 1 |
| Sanders, SJ | 1 |
| Fernandez, TV | 1 |
| Ji, W | 1 |
| Lifton, RP | 1 |
| Vadasz, E | 1 |
| Dietrich, A | 1 |
| Pradhan, D | 1 |
| Song, H | 1 |
| Ming, GL | 1 |
| Haddad, G | 1 |
| Marchetto, MC | 1 |
| Spitzer, N | 1 |
| Passos-Bueno, MR | 1 |
| State, MW | 1 |
| Muotri, AR | 1 |
| Zhang, W | 1 |
| Chen, Z | 1 |
| Chen, L | 1 |
| Wang, F | 1 |
| Li, F | 1 |
| Wang, X | 1 |
| Fu, L | 1 |
| Pinto, AC | 1 |
| Moreira, JN | 1 |
| Simões, S | 1 |
| Krukemeyer, MG | 1 |
| Krenn, V | 1 |
| Jakobs, M | 1 |
| Wagner, W | 1 |
| Kiraly, A | 1 |
| Koffman, B | 1 |
| Hacker, M | 1 |
| Gunning, W | 1 |
| Rasche, S | 1 |
| Quinn, A | 1 |
| Langer, SW | 1 |
| Thougaard, AV | 1 |
| Sehested, M | 1 |
| Jensen, PB | 1 |
| Henry, CJ | 1 |
| McCaw, DL | 1 |
| Turnquist, SE | 1 |
| Tyler, JW | 1 |
| Bravo, L | 1 |
| Sheafor, S | 1 |
| Straw, RC | 1 |
| Dernell, WS | 1 |
| Madewell, BR | 1 |
| Jorgensen, L | 1 |
| Scott, MA | 1 |
| Higginbotham, ML | 1 |
| Chun, R | 1 |
| Confavreux, C | 1 |
| Vukusic, S | 1 |
| Scott, LJ | 1 |
| Figgitt, DP | 1 |
| Gonsette, RE | 1 |
| Dubois, B | 1 |
| Webb, M | 1 |
| Tham, CS | 1 |
| Lin, FF | 1 |
| Lariosa-Willingham, K | 1 |
| Yu, N | 1 |
| Hale, J | 1 |
| Mandala, S | 1 |
| Chun, J | 1 |
| Rao, TS | 1 |
| Saini, M | 1 |
| Roser, F | 1 |
| Hussein, S | 1 |
| Samii, M | 1 |
| Bellinzona, M | 1 |
| Dirsch, O | 1 |
| Dahmen, U | 1 |
| Gu, YL | 1 |
| Ji, Y | 1 |
| Karoussos, IA | 1 |
| Wieneke, H | 1 |
| Erbel, R | 1 |
| Tonn, JC | 1 |
| Schönmayr, R | 1 |
| Braun, R | 1 |
| Kraemer, HP | 1 |
| Ehninger, G | 1 |
| Aguila, B | 1 |
| Coulbault, L | 1 |
| Boulouard, M | 1 |
| Léveillé, F | 1 |
| Davis, A | 1 |
| Tóth, G | 1 |
| Borsodi, A | 1 |
| Balboni, G | 1 |
| Salvadori, S | 1 |
| Jauzac, P | 1 |
| Allouche, S | 1 |
| Piao, WH | 1 |
| Wong, R | 1 |
| Huang, J | 1 |
| Campagnolo, DI | 1 |
| Dorr, RT | 1 |
| Vollmer, TL | 1 |
| Shi, FD | 1 |
| Bai, S | 1 |
| Zhang, X | 1 |
| Xie, C | 1 |
| Hou, S | 1 |
| Zhang, Z | 1 |
| Liao, G | 1 |
| Volz, J | 1 |
| Volz-Köster, S | 1 |
| Kanis, S | 1 |
| Klee, D | 1 |
| Ahlert, C | 1 |
| Melchert, F | 1 |
| Jin, G | 1 |
| You, Y | 1 |
| Ahn, B | 1 |
| Hemmer, B | 1 |
| Cepok, S | 1 |
| Nessler, S | 1 |
| Sommer, N | 1 |
| Schally, AV | 1 |
| Kook, AI | 1 |
| Monje, E | 1 |
| Redding, TW | 1 |
| Paz-Bouza, JI | 1 |
| Sloboda, AE | 1 |
| Oronsky, AL | 1 |
| Kerwar, SS | 1 |
3 reviews available for mitoxantrone and Disease Models, Animal
| Article | Year |
|---|---|
Mitoxantrone: a review of its use in multiple sclerosis.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Databases as Topic; Disease Models, Animal | 2004 |
Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Heart; Humans; Immunosuppressive Agents; | 2004 |
DNA topoisomerase II inhibitors.
Topics: Amsacrine; Antineoplastic Agents; Carcinogens; Disease Models, Animal; Etoposide; Evidence-Based Med | 2000 |
28 other studies available for mitoxantrone and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.
Topics: Animals; Cardiotoxicity; Cell Line, Tumor; Disease Models, Animal; Heart Injuries; Humans; Mice; Mit | 2017 |
Vaccination With Mitoxantrone-Treated Primary Colon Cancer Cells Enhances Tumor-Infiltrating Lymphocytes and Clinical Responses in Colorectal Liver Metastases.
Topics: Animals; Antineoplastic Agents; Cancer Vaccines; Cell Cycle Checkpoints; Cell Line, Tumor; Colorecta | 2019 |
Identification and evaluation of antivirals for Rift Valley fever virus.
Topics: Animals; Antiviral Agents; Azauridine; Cell Line; Disease Models, Animal; Drug Discovery; Female; Hi | 2019 |
MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily | 2013 |
Is there B cell involvement in a rat model of spontaneous idiopathic nephrotic syndrome treated with LF15-0195?
Topics: Adoptive Transfer; Animals; B-Lymphocytes; Disease Models, Animal; Gene Expression Regulation; Guani | 2014 |
Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Bithionol; Cells, | 2015 |
Modeling non-syndromic autism and the impact of TRPC6 disruption in human neurons.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autistic Disorder; Carboplatin; Cell Differ | 2015 |
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, | 2017 |
Liposomal imatinib-mitoxantrone combination: formulation development and therapeutic evaluation in an animal model of prostate cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benz | 2011 |
Mitoxantrone-iron oxide biodistribution in blood, tumor, spleen, and liver--magnetic nanoparticles in cancer treatment.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Drug Delivery Systems; Ferric Compounds; Liv | 2012 |
A novel aza-anthrapyrazole blocks the progression of experimental autoimmune encephalomyelitis after the priming of autoimmunity.
Topics: Animals; Autoimmunity; Cytokines; Disease Models, Animal; Disease Progression; Encephalomyelitis, Au | 2011 |
Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.
Topics: Animals; Anthracyclines; Antineoplastic Agents; Disease Models, Animal; Doxorubicin; Extravasation o | 2012 |
Clinical evaluation of mitoxantrone and piroxicam in a canine model of human invasive urinary bladder carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Disease Models, Animal; Dogs; Female; | 2003 |
[Multiple sclerosis (MS), an inflammatory or degenerative disease?].
Topics: Adjuvants, Immunologic; Adult; Animals; Chronic Disease; Cohort Studies; Disease Models, Animal; For | 2004 |
Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Inter | 2004 |
Intralesional mitoxantrone biopolymer-mediated chemotherapy prolongs survival in rats with experimental brain tumors.
Topics: Animals; Antineoplastic Agents; Biopolymers; Brain Neoplasms; Delayed-Action Preparations; Disease M | 2004 |
Preliminary investigation of mitoxantrone coating on stent-grafts to inhibit neointimal proliferation.
Topics: Animals; Biopsy, Needle; Carotid Stenosis; Catheterization; Cell Proliferation; Coated Materials, Bi | 2005 |
Brain tissue concentration of mitoxantrone in the rat in relation to in vitro chemosensitivity of malignant human intracranial tumors--preliminary results.
Topics: Animals; Brain; Brain Neoplasms; Disease Models, Animal; Humans; Male; Mitoxantrone; Rats; Rats, Wis | 1989 |
In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.
Topics: Animals; Antidepressive Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bind | 2007 |
Therapeutic effect of anthracene-based anticancer agent ethonafide in an animal model of multiple sclerosis.
Topics: Acute Disease; Animals; Anthracenes; Antineoplastic Agents; Disease Models, Animal; Dose-Response Re | 2007 |
[A model of orthotopic transplantation of human hepatoma established in nude mice tumor inhibition studies].
Topics: Animals; Disease Models, Animal; Drug Delivery Systems; Humans; Liver Neoplasms; Mice; Mice, Inbred | 1993 |
Modulation of tumor-induced lethality after pneumoperitoneum in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Disease Models, Animal; Fema | 2000 |
Esters of 2-(1-hydroxyalkyl)-1,4-dihydroxy-9,10-anthraquinones with melphalan as multifunctional anticancer agents.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Disease Models, Animal; Esters; Leukemia L1210; Melp | 2001 |
[New approaches in research of therapy of multiple sclerosis].
Topics: Adjuvants, Immunologic; Adult; Animals; Clinical Trials, Phase III as Topic; Disease Models, Animal; | 2001 |
Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Capsules; Delayed-Action Preparations; Dise | 1986 |
Studies of the effect of mitoxantrone on adjuvant induced arthritis in rats.
Topics: Animals; Anthraquinones; Anti-Inflammatory Agents; Arthritis; Arthritis, Experimental; Arthritis, Rh | 1986 |